PEG-MGF (Pegylated Mechano Growth Factor)

Structure: Synthetic version of the C-terminal 24-amino-acid E-domain of the IGF-1Ec splice variant (MGF), conjugated to polyethylene glycol (PEG). PEGylation slows enzymatic degradation and renal clearance, extending the in-vivo half-life from minutes to hours.

How it differs from "MGF" in the catalog:

• Native MGF (slug: mgf): unmodified peptide, ~5 to 7 minute half-life, must be injected directly into the trained muscle within ~10 minutes of finishing the workout to have any plausible effect
• PEG-MGF (this entry): pegylated, ~24 to 48 hour half-life, can be injected SubQ post-workout (does not need to be intramuscular into the trained muscle)
• Most grey-market product sold as "MGF" is actually PEG-MGF, since native MGF is impractical to dose

Dosage:

• Standard: 200 to 400mcg post-workout, SubQ
• Aggressive: 200mcg 2 to 3 times per week, on training days only
• Cycle: 4 to 6 weeks on, 2 to 4 weeks off (anecdotal; no clinical guidance exists)

Administration:

• SubQ injection, abdomen, immediately post-workout (within ~30 minutes)
• 27 to 30g insulin syringe
• Some users still inject IM into the trained muscle, though the extended half-life of PEG-MGF makes this unnecessary
• Reconstitute with bacteriostatic water, refrigerate, use within 30 days

Key Notes:

• Proposed mechanism: activates muscle satellite cells (Pax7+ stem cells) so they proliferate and fuse with existing fibres, contributing to hyperplasia and faster repair. Most evidence is from cell culture and rodent studies of native MGF, not PEGylated forms.
• Human clinical data on injected PEG-MGF is essentially non-existent. Confidence in efficacy for hypertrophy in healthy adults is low.
• Often stacked with IGF-1 LR3, GH, or GHRH/GHRP combinations. Attribution of muscle gain to PEG-MGF alone is difficult in user reports.
• Should not directly raise systemic IGF-1, so does not produce the GH-like sides (water retention, joint pain, glucose impairment) expected from IGF-1 LR3 or exogenous GH.
• Allergic reactions to PEG itself have been reported with various PEGylated drugs. Discontinue if injection-site induration or systemic hypersensitivity occurs.
• Monitor: no specific bloodwork changes expected from PEG-MGF alone. If stacked with GH or IGF-1 LR3, monitor IGF-1, fasting glucose, and HbA1c.

References:

• Goldspink, G. (2005). Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 20, 232-238. DOI: 10.1152/physiol.00004.2005
• Hill, M., & Goldspink, G. (2003). Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. Journal of Physiology, 549(Pt 2), 409-418. DOI: 10.1113/jphysiol.2002.035832
• Yang, S. Y., & Goldspink, G. (2002). Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Letters, 522(1-3), 156-160. DOI: 10.1016/S0014-5793(02)02918-6
• Veronese, F. M., & Pasut, G. (2005). PEGylation, successful approach to drug delivery. Drug Discovery Today, 10(21), 1451-1458. DOI: 10.1016/S1359-6446(05)03575-0